To broaden the scope of its research, Hemerion funds initiatives and projects led by scientists or clinical teams capable of offering new perspectives on concrete challenges in the fight against cancer. Following a successful first edition in 2025, which recognized one American team and one European team, Hemerion is preparing for a second, more expansive …
Hemerion’s participation in the American Association of Neurological Surgeons (AANS) Annual Meeting from May 1 to 4, 2026, allowed our team to strengthen ties with international clinicians and showcase its Pentalafen® / Heliance® combination therapy to major industry players in the neurosurgery sector. The AANS conference is one of the highlights of the neurosurgery calendar …
Upon returning from the annual meeting of the American Association of Neurological Surgeons (AANS) held in San Diego, Hemerion continued its expansion into the U.S. market. Maximilien Vermandel and Patrick Tricoli, recently appointed Senior Advisor for Strategy and Corporate Development, led a mission to Boston, the cradle of healthcare innovation, with the aim of strengthening …
The latest Independent Data and Safety Monitoring Board (iDSMB) meeting confirmed that Hemerion completed patient enrollment in its HTX-GBM-01 clinical trial of the Pentalafen/Heliance therapy for the treatment of glioblastoma. This major milestone validates Hemerion’s clinical roadmap, which aims for a U.S. market launch in 2030. On April 16, 2026, the Independent Data and Safety …
On April 20, 2026, Hemerion received approval from the EMA (European Medicines Agency) expert panel regarding Orphan Medical Device status for its Heliance illumination platform, used in photodynamic therapy (PDT) for the treatment of operable newly diagnosed glioblastoma. Hemerion has become one of the first European healthtech companies to benefit from this new status, which …
Patrick Tricoli, PharmD, MBA, a long-time Boston resident, is joining our team as Senior Advisor for Strategy & Corporate Development.He brings his in-depth knowledge of the U.S. market and unique perspective on business development to Hemerion. These assets are essential for accelerating our expansion in the U.S. and forging new strategic partnerships. Patrick Tricoli, a …
Hemerion is participating for the first time in the American Association of Neurological Surgeons (AANS) Annual Meeting, held in San Antonio, Texas, from May 1 to 4, 2026.This major event marks a continued expansion of our international clinical network. Our ultimate goal is to launch a pivotal trial for the Pentalafen/Heliance therapy, which represents the …
After receiving several positive feedback from European and US health agencies, Hemerion is preparing to scale up its teams for the implementation of a pivotal clinical trial, the last step before the market authorization of its flagship therapy Pentalafen / Heliance. To structure the implementation of the pivotal clinical trial giving access to the American …
The Food and Drug Administration (FDA) has issued a positive feedback on Hemerion’s clinical strategy following a Type C Meeting held in November 2025. The U.S. health authority confirmed the relevance of Hemerion’s proposed clinical and regulatory strategy for the Pentalafen® / Heliance® technology in the treatment of newly diagnosed glioblastoma patients in the United …
A newly published case report in the renowned Journal of Neuro-Oncology Discovery provides compelling clinical evidence of the feasibility, safety and workflow integration of the Pentalafen®/Heliance® combination therapy in treating glioblastoma. This case, drawn from the Hemerion-sponsored Phase 1/2 clinical trial at the University of Pittsburgh Medical Center, highlights the potential of Hemerion’s technology to …